Stéphane Ragusa, CEO of Predilife, opens the trading day in Paris

Predilife lists on Euronext Growth on December 21st, 2018.

Predilife specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of 1,000,000 American women and 350,000 French women.